Qing-Sheng Mi, MD, PhD

Professor and Senior Scientist
Director, Henry Ford Immunology Program
Director of Research, Department of Dermatology
Department of Internal Medicine
Henry Ford Health System, Department of Immunology and Microbiology
Wayne State University School of Medicine
Detroit, MI 48202, USA

 

Biography

Dr. Mi is a Professor and Senior Scientist, Director of Henry Ford Immunology Program, Director of Dermatology Research, Dept of Dermatology, Dept of Internal Medicine, Henry Ford Health System (HFHS); Dept of Immunology and Microbiology, Wayne State University. Dr. Mi received his MD from Taishan Medical College in 1985 and his PhD in Immunodermatology from China Medical University in 1992. He was an Assistant Professor, Associate Professor and Professor, Dept of Dermatology, Taishan Medical College (1991-1996); a Visiting Associate Scientist, Laboratory of Immunology, National Aging Institute/NIH supported by NIH Fogarty International Scholarship (1996-2000); Senior Research Associate, Autoimmunity Group, Robert Research Institute in Canada (2000-2003); Assistant Professor and Associate professor in Dept of Pathology and Dept of Dermatology, Medical College of Georgia (2003-2008). He joined in Henry Ford Health System since 2008, and established Henry Ford Immunology Program. Dr. Mi is an author on over 100 publications, including Nat Med, PNAS, and Hepatology. He serves as associate editors or member of editorial boards in numerous Journals and is an Ad hoc grant reviewer for NSF (China), MRC (United Kingdom), BBRC (United Kingdom), and SNFS (Switzerland).

Research Interest

His current research interests include: epigenetic (miRNAs/HDACs) immune regulation (especially in NKT cells and epidermal langerhans cells) and miRNA biomarkers for human diseases, which are funded by NIH, Melanoma Research Alliance, JDRF, and Vitiligo Research Foundation.

Scientific Activities

AWARDS AND HONORS

• (1992) Young Scientist Scholarship by 18th Word Congress of Dermatology , NY, USA
• (1993) The first prize of Advancement of Science and Technology by Taishan Medical college
• (1993) The third prize of the Advancement of Science and Technology by Shandong Province Education Committee
• (1993) Nominated 1993 Shandong Provinces top ten talent youngster
• The first prize of the Advancement of Science and Technology by Taishan Medical college
• (1994) The first prize of the Advancement of Science and Technology by the Education Committee Shandong Province (1994, Jinan)
• (1994) 1994 Taian Citys top ten young talent scientists
• (1995) The third prize of the Advancement of Science and Technology by the Ministry of Education, P. R. China
• (1996-2000) NIH John Fogarty International Scholarship for Foreign Scientists
• (1999) Staff recognition award by National Institutes of Health, MD, USA
• (2000) Scholar of “Sunshine program” for oversea scientists, Ministry of Education, P. R. China
• (2000-2003) Research Scholarship, Ontario Research and Development Challenge Fund, Canada
• (2003) NIH funded Scholarship in 2003 Keystone Symposia: Mechanism of immunologic tolerance and its breakdown, Snowbird, UT
• (2004) Junior Faculty Travel Award, 12th International Congress of Immunology, Montreal, Canada
• (2005) Junior Faculty Travel Award, Annual meeting, American Association of Immunologist (AAI), San Diego
• (2006) Junior Faculty Travel Award, 2006 Annual meeting, AAI, Boston
• (2011) Laboratory Travel Award, 2011 Annual meeting, AAI, San Francisco
• (2012) Laboratory Travel Award, 2012 Annual meeting, AAI, Boston
• (2013) Member of Steering Committee, Biomarker Working Group, Juvenile Diabetes Research Foundation International
• (2015) Laboratory Travel Award, Annual meeting of AAI, New Orleans

Publications

PEER-REVIEWED ORIGINAL ARTICLES

1. Mi QS, Chen M. Study on the immunopathology of erythema induratum. Chin J Dermatol. 1991; 24(6): 366-368.
2. Mi QS, Chen M, Chen H-D. Langerhans cells in the lesions of erythema induratum. Chin J Med. 1992; 72(2): 104-105.
3. Mi QS, Chen M, Chen H-D. RBC immune and skin diseases (review) J Clin Dermatol. 1993; 21(3): 206-208.
4. Mi QS, Chen M, Chen H-D. Investigation of circulating and tissue-deposited immune complexes in erythema induratum. J Taishan Med Col. 1994; 15(1): 68-71.
5. Mi QS, Chen M, Chen H-D. Immunohistochemical analysis of T cells subsets in the lesions of erythema induratum. Chin J Dermatol. 1994; 27(3): 193-194.
6. Mi QS, Chen M, Chen H-D. The detection of antibodies to mycobactrium tuberculosis in serum of erythema induratum by ELISA. Chin J Dermatol. 1994; 27(5): 295-297.
7. J. Gu, Mi QS, Chen M. Investigation on DNA of M. tuberculosis in the lesions of erythema induratum using PCR. Chin J Dermatol. 1994; 27(5): 294-295.
8. Mi QS, Chen M, Chen H-D. Immunosuppressant-FK506 and its clinic administration (review). International Dermatol. 1994; 20(4): 203-205. doi:10.5021/ad.2014.26.2.203
9. Mi QS, Chen M, Chen H-D. Study on the immune complexe cutaneous vasculitis. Chin J Immunol. 1995; 11(5): 239-242.
10. Mi QS, Chen M, Chen H-D. Immunolight and immunoelectronic microscopic identification of Langerhans cells in the subcutaneous infiltrates in erythema induratum. Chin J Dermatovenerol. 1995; 9(3): 130-131.
11. Mi QS, Zhang XZ. Study of etiology of NGU in Taian. J Taishan Med Col. 1995; 16(3): 219-216.
12. Mi QS, Gu J, Chen M. Studies on the clinic and pathology of erythema induratum. Chinese J Dermatol. 1995; 28(5): 305-306.
13. Mi QS, Pan J-C. Clinic and pathological analysis of 16 cases with pseudo-condyloma of vulva. Current Advance in obstetrics and gynecology. 1995; 4(4): 315-317.
14. Mi QS, Li H-L. Treatment efficient of Ofloxacin to ureaplas urealyticum urethritis/vaginitis. Modern Applied pharmacy. 1995; 12(4): 30-31.
15. Mi QS, Gu J. The detection of anti-PPD antibodies in the serum of skin tuberculosis and its clinic significance. J Taishan Med Col. 1995; 16(2): 102-105.
16. Mi QS, Zhou L, Chen H-D. Antisense technique and the therapy of skin virus diseases (review). Foreign Med: Dermatol. 1996; 22(2): 102-105.
17. Mi QS, Wang Y-K Chen, H-D. Effects of FK506 on dendritic epidermal T cells in mice. Chin J Dermatol. 1996; 29(6): 427-429.
18. Li HL, Mi QS. Detection of chlaydia trachomatis in patients with NGU. J Taishan Med Col. 1996; 17(3): 215-216.
19. Duo FL, Zen ZX, Meng J, et al. Treatment of 20 cases of vitiligo by auto-epidermal grafting. Huaihai Medicine. 1997; 15(3): 17-18.
20. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. USA. 1999; 96: 3775-3780.
21. Mi QS, Zhou L, Schulze DH, et al. Highly reduced protection against Streptococcus pneumoniae following deletion of a single heavy chain gene in mouse. Proc. Natl. Acad. Sci. USA. 2000; 97(11): 6031-6036.
22. Sharif S, Arreaza GA, Zucker P, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 2001; 7(9): 1057-1062. doi: 10.1038/nm0901-1057
23. Zhou L, Rowley DL, Mi QS, et al. Murine inter-strain polymorphisms alter gene targeting frequencies at the mu opioid receptor locus in embryonic stem cells. Mamm Genome. 2001; 12(10): 772-778. doi:10.1007/s00335-001-1003-8
24. Hu L, Rezanka LJ, Mi QS, et al. T15-Idiotype-Negative B Cells Dominate the Phosphocholine Binding Cells in the Preimmune Repertoire of T15i Knockin Mice. J Immunol. 2002; 168(3): 1273-1280. doi:10.4049/jimmunol.168.3.1273
25. Sharif S, Arreaza GA, Zucker P, Mi QS, Delovitch TL. Regulation of Autoimmune Disease by Nature Killer T Cells. J Mol Med. 2002; 80(5): 290-300. doi:10.1007/s00109-002-0332-8
26. Gu J, Bi XL, Chen ZQ, Mi QS. Effects of Trivalent Arsenicals on Cell Proliferation and Apoptosis in Human Epidermal Keratinocytes. Chin J Dermatol. 2002; 35(6): 457-459.
27. Mi QS, Rezanka LJ, Fisher RT, Lustig A, Longo DL, Kenny JJ. Anti-phosphocholine M603 idotype is lost in terminal deoxynucleotidyl transferase gene deficient mice. Eur J Immunol. 2002; 32(4): 1139-1146.
28. Weng JH, Zhang LZ, Bi XL, Gu J, Mi QS. Effects of Arsenic on Cell Proliferation and Secretion of IL-8 and TNF-α in Cultured Keratinocytes. Chin J Dermatovenerol Integrated Traditional and Western Med. 2002; 1(1).
29. Grattan M, Mi QS, Meagher C, Delovitch TL. Congenic Mapping of the Diabetogenic Locus Idd4 to a 5.2-cM Region of Chromosome 11 in NOD Mice: Identification of Two Potential Candidate Subloci. Diabetes. 2002; 51(1): 215-223. doi:10.2337/diabetes.51.1.215
30. Gu J, Bi XL, Mi QS, Wen JH. Effects of Arsenic on Cell Proliferation and Its Related Gene Expression in Human Epidermal Keratinocyte. Chin J Integrated Traditional and Western Med. 2002; 3(1): 35-40.
31. Zhou L, Népote V, Rowley DL et al. Murine Peripherin gene sequences direct Cre recombinase expression to peripheral neurons in transgenic mice. FEBS Letters. 2002; 523(1-3): 68-72. doi:10.1016/S0014-5793(02)02936-8
32. Chen QF, Gu J, Mi QS. NKT cells and psoriasis. International Dermatol. 2003; 29(2): 103-105.
33. Wang ZD, Gu J, Mi QS. Effect of immunosuppressant-FK506 on NO secretion of HaCaT cell induced by TNF-α. China J Leprosy Skin Diseases. 2002; 25(3): 25-27.
34. Bin XL, Guo J, Mi QS. Advance of curcumin in the prevention and treatment of skin cancer. Chin J Dermatovenerol Integrated Traditional and Western Med. 2003; 2(2): 130-132.
35. Arreaza G, Yang W, Salojin KV, et al. Resistance of T cells to T cells receptor activation induced apoptosis in Nonobes diabetes mice: possible role in the pathogenesis of type 1 diabetes. Clin Immunol. 2003; 107: 103-115.
36. Gu J, Bi XL, Mi QS. Activation of ERK and related signal trasduction in keratinocytes by arsenite. Chin J Dermatol. 2003; 36(6): 347-348.
37. Mi QS, Ly DL, Salojin K, Chen YH, Taub DD, Delovitch TL. Blockade of TRAIL exacerbates the onset of diabetes in NOD mice. Diabetes. 2003; 52(8): 1967-1975.
38. Guo ZL, Gu J, Mi QS. Effects of leftunomide on NFkB of human keratinocytes. Chin J Dermatol. 2003; 36(11): 653-654.
39. Bin XL, Guo J, Mi QS. Effects of arsenic on DNA sythesis and E2F1 expression in human epidermal keratinocytes. Chin J Dermatol Venereol. 2003; 17(1): 9-11.
40. Chen W, Salojin K, Mi QS, et al. IGF-I/IGF-Binding Protein-3 (IGFBP-3) Complex: Therapeutic Efficacy and Mechanism of Protection against Type 1 Diabetes. Endocrinology. 2003.
41. Guo ZL, Gu J, Mi QS. Effects of Leflunomide on the Proliferation and Apoptosis of Human Keratinocytes. Chin J Dermatol. 2003; 36(10): 580-582.
42. Mi QS, Meagher C, Delovitch TL. CD1d restricted NKT regulatory cells: functional genomic analyses provide new insight into mechanism of protection against type 1 diabetes. Novartis Found Symp. 2003; 252: 146-160.
43. Bin XL, Guo J, Nie BY, Li Q, Liu B, Mi QS. Effects of Baicalin on Expression of Inducible Nitric Oxide Synthase in Cultured Fibroblasts Stimulated by Cytokines. Chin J Integrative Med. 2004; 10(6): 40-43. doi:10.1007/BF02836558
44. Lin DD, Bi XL, Gu J, Liao MY, Mi QS. Variant of PAF-AH Activity in the Patients with Psoriasis and Its Clinical Significance. Chin J Derm Venereo1. 2004; 18(7): 387-388.
45. Chen W, Salojin K, Mi QS, et al. IGF-I/IGF-Binding Protein-3 (IGFBP-3) Complex: Therapeutic Efficacy and Mechanism of Protection against Type 1 Diabetes. Endocrinology. 2004; 145(2): 627-638.
46. Jing L, Hu JH, Zhu QG, Feng F, Gu J, Mi QS. Expression and regulation of platet-activating factor receptor in human heratinocytes. Acad J Sec Mil Med Univ. 2004; 25(6): 612-615.
47. Mi QS, Ly DL, Delovitch TL. Differential requirements of IL-10 and IL-4 are exist for protection against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant nature killer T cell. Diabetes. 2004; 53(5): 1303-1310.
48. Guo ZL, Gu J, Tang L, Qiu Y, Mi QS. Effects of leflunmide on secretion of TNF-a, IL-6 and IL-8 in HaCaT cells. J Clin Dermatol. 2004; 33(1): 9-10.
49. Yang W, Hussain S, Mi QS, Santamaria P, Delovitch TL. Perturbed Homeostasis of Peripheral T Cells Elicits Decreased Susceptibility to Anti-CD3-Induced Apoptosis in Prediabetic Nonobese Diabetic Mice. J Immunol. 2004; 173(7): 4407-4016. doi:10.4049/jimmunol.173.7.4407
50. Guo ZL, Gu J, Zhu HY, Cao YF, Mi QS, Xiao F. Regulation of nuclear factor-kappa B translation in HaCat cells by Leflunomide metabolite A771726. Chin J Dermatol. 2005; 38(1): 53.
51. Ma SW, Huang Y, Davis A, et al. Production of biologically active human interleukin-4 in transgenic tobacco and potato. Plant Biotechnology J. 2005; 3(3): 309-318. doi:10.1111/j.1467-7652.2005.00125.x
52. Lin DD, Bin XL, Zhu KJ, Liao MY, Mi QS, Gu J. Association of Val279PHe Missense Mutation in the Platelet-Activating Factor Acetylhydrolase Gene with Genetic Susceptibility to Psoriasis. Chin J Dermatol. 2005; 38(3): 151-153.
53. Bin XL, Gu J, Mi QS. Expression of mu-opiate receptor in human keratinocyte cell lines. J Clin Dermatol. 2005; 34(3): 137-138.
54. Ding KH, Wang ZZ, Hamrick MW, et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun. 2006; 340(4): 1091-1097. doi:10.1016/j.bbrc.2005.12.107
55. Ly D, Hussain S, Mi QS, Delovitch TL. Protection from Type 1 Diabetes by iNKT Cells Requires the Activity of CD4+CD25+ Regulatory T Cells. J Immunol. 2006; 177(6): 3695-3704. doi:10.4049/jimmunol.177.6.3695
56. Mi QS, Zhou L, Grattan M, Wang ZZ, She JX, Delovitch TL. Characterization of PAF-AH1b1 in NOD Mice: PAF-AH1b1 may be not a Candidate Gene of the Idd4.1 Locus. Ann N Y Acad Sci. 2006; 1079: 147-152.
57. Meagher C, Arreaza G, Mi QS, et al. CCL4 Protects from Type 1 Diabetes by Altering Islet Beta Cell Targeted Inflammatory Responses. Diabetes. 2007; 56(3): 809-817.
58. Ding KH, Shi XM, ZHong Q, et al. Impact of Glucose- dependent Insulinotropic Peptide on Age- induced Bone Loss. J Bone Miner Res. 2008; 23(4): 536-543. doi:10.1359/jbmr.071202
59. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem. 2008; 283(10): 6572-6583.
60. Liu YY, Bi XL, Mi QS, Gu J. Effect of arotinoid trometamol on the expression of genes in human keratinocytes. Zhonghua Yi Xue Za Zhi. 2008; 88(4): 276-278.
61. Zhang W, Hamrick M, Hill W, et al. Age-Related Changes in the Osteogenic Differentiation Potential of Mouse Bone Marrow Mesenchymal Stem Cells. J Bone Miner Res. 2008; 23(7): 1118-1128. doi:10.1359/JBMR.080304
62. Zhou L, H He, XF Mi, CG Li, B Lee, QS Mi. microRNAs: diabetes susceptibility candidates in human type 1 diabetes. Ann N Y Acad Sci. 2008; 1150: 72-75.
63. Zhou L, Wang H, Zhong X, et al. The Il-10 and IFN-gamma pathways are essential to the potent immunosuppressive activity of cultured CD8+ NKT-like cells. Genome Biol. 2008; 9(7): R119.
64. Zhou L, Seo KH, He HZ, et al. Tie2cre-induced inactivation of the miRNA-processing enzyme Dicer disrupts invariant NKT cell development. Proc. Natl. Acad. Sci. USA. 2009; 106(25): 10266-10271.
65. Miao ZM, Zhao SH, Yan SL, et al. NALP3 inflammasome functional mutation and gout susceptibility. Cell Cycle. 2009; 8(1): 27-30.
66. Zhou L, Seo KH, Wong H, Lim HW, Mi QS. MicroRNAs and immune regulatory T cells. Int Immunopharmacol. 2009; 9(5): 524-527. doi:10.1016/j.intimp.2009.01.017
67. Mi QS, Yan SL, Wang ZZ, et al. Spontaneous bone loss in RIP-iNOS transgenic mouse: a mouse model for diabetes-mediated osteopenia/osteoporosis. Cell Cycle. 2009; 8(24): 4179-4181.
68. Li C, Han L, Levin AM, et al. Multiple single nucleotide polymorphisms in the human urate transporter 1 (hURAT1) gene are associated with hyperuricemia in Han Chinese. J Med Genetics. 2010. doi:10.1136/jmg.2009.068619
69. Bi X, Gu J, Mi QS. Different pathways are involved in arsenic trioxide-induced cell proliferation and growth inhibition in human keratinocytes. Skin Pharmacol and Physiol. 2009; 23(2): 68-78. doi:10.1159/000265677
70. Bhatt K, Zhou L, Mi QS, Huang S, She JX, Dong Z. microRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol Med. 2010; 16(9-10): 409-416. doi:10.2119/molmed.2010.00002.
71. Wei Q, Bhatt K, He HZ, Mi QS, Haase VH, Dong Z. Targeted Deletion of Dicer from Proximal Tubules Protects against Renal Ischemia-Reperfusion Injury. J Am Soc Nephrol. 2010; 21(5): 756-761.
72. Zhao X, He X, Han X, et al. MicroRNA-mediated control of oligodendrocyte differentiation. Neuron. 2010; 65(5): 612-626. doi:10.1016/j.neuron.2010.02.018
73. Mi QS, He HZ, Dong Z, Isales C, Zhou L. microRNAs deficiency in pancreatic islet cells exacerbates streptozotocin-induced murine autoimmune diabetes. Cell Cycle. 2010; 9(15): 3127-3129. doi:10.4161/cc.9.15.12596
74. Seo KH, Zhou L, Meng DM, Xu J, Mi QS. Loss of microRNAs in thymus perturbs invariant NKT cell development and function. Cell Mol Immuol. 2010; 7(6): 447-453. doi:10.1038/cmi.2010.49
75. Meagher C, Beilke J, Arreaza G, et al. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes. 2010; 59(11): 2862-2871. doi:10.2337/db09-0131
76. Hamrick MW1, Herberg S, Arounleut P, et al. The Adipokine Leptin Increases Skeletal Muscle Mass and Significantly Alters Skeletal Muscle miRNA Expression Profile in Aged Mice. Biochem Biophys Res Commun. 2010; 400(3): 379-383. doi:10.1016/j.bbrc.2010.08.079
77. Wang L, Yan SL, Wang F, Mi QS. Effect of a high-fat diet on bone development in young mice. J Clinical Rehabilitative Tissue Engineering Research. 2011; 15(7): 1321-1325.
78. Li K, Seo KH, Gao TW, et al. NKT cell development and function in miR-223 knockout mice. Int Immunopharmacol. 2011; 11(5): 561-568.
79. Bhatt K, Mi QS, Dong Z. Invited Review- microRNAs in kidneys: biogenesis, regulation and pathophysiological roles. Am J Physiol Renal Physiol. 2011; 300(3): F602-F610. doi:10.1152/ajprenal.00727.2010
80. Zhou L, Park JY, Zheng QH, Mi QS. miRNAs regulate NKT and Foxp3 Treg cell development and function. Cell Mol Immuno. 2011; 8(5): 380-387. doi:10.1038/cmi.2011.27
81. Qi RQ, He L, Zheng S, et al. BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J Invest Dermatol. 2011; 131(5): 1129-1138.
82. Mi X, He H, Deng Y, et al. Lack of an association of miR-938 SNP in IDDM10 with human type 1 diabetes. Diabetol Metab Syndr. 2011; 3(1): 27.
83. Gao N, Yin J, Yoon GS, Mi QS, Yu FS. Dendritic Cell-epithelium Interplay Is a Determinant Factor for Corneal Epithelial Wound Repair. Am. J. Pathol. 2011; 179(5): 2243-2253. doi:10.1016/j.ajpath.2011.07.050
84. Qi RQ, Liu M, Gao XH, et al. Histone deacetylase activity is required for skin Langerhans cell maturation and phagocytosis. J Dermtol Sci. 2012; 65(2): 152-155. doi:10.1016/j.jdermsci.2011.11.009
85. Qi R, Weiland M, Gao XH, Zhou L, Mi QS. Identification of endogenous normalizers for serum miRNAs by microarray profiling: U6 snRNA is not a reliable normalizer. Hepatology. 2012; 255(5): 1640-1642. doi:10.1002/hep.25558.
86. Zhen QH, Zhou L, Mi QS. microRNA miR-150 regulates NKT cell development and function. J Immunol. 2012; 188(5): 2118-2126.
87. Mi QS, Weiland M, Qi R, Gao XH, Poisson LM, Zhou L. Identification of mouse serum miRNA endogenous references by global gene expression profiles. PLOS One. 2012; 7(2): e31278.
88. Xu YP, Shi YL, Li L, Zhou L, Mi QS. TGFβ/Smad3 Pathway is not required for epidermal Langerhans cell development. J Invest Dermatol. 2012; 132(8): 2106-2109. doi:10.1038/jid.2012.71
89. Mi QS, Xu YP, Qi R, Zhou L. MicroRNA miR-150 is required for skin Langerhans cell cross-presentation. Exp Dermatol. 2012; 21: 876-878.
90. Shi YL, Gu J, Park J, et al. Histone deacetylase inhibitor trichostatin A ameliorates contact dermatitis and reduces langerhans cells in mice, J Dermatol Sci. 2012; 68: 99-107.
91. Zhang L, Yang M, Marks P, et al. Serum non-coding RNAs as biomarkers for osteoarthritis progression after ACL injury. Osteoarthritis Cartilage. 2012; 20(12): 1631-1637. doi:10.1016/j.joca.2012.08.016
92. Ozog DM, Liu A, Chaffins ML, et al. Evaluation of Clinical Results, Mature Burn Scar Histology and Collagen Expression Following Treatment with a Fractional Carbon Dioxide Laser. Arch Dermatol. 2012; 15: 1-8.
93. Qu L, Liu A, Zhou L, et al. Clinical and Molecular Effects on Mature Burn Scars after Treatment with a Fractional CO2 Laser. Lasers Surg Med. 2012; 44(7): 517-524. doi:10.1002/lsm.22055
94. Weiland M, Gao XH, Zhou L, Mi QS. Small RNA has a big impact: serum miRNAs as biomarkers for human diseases. RNA Biol. 2012; 9(6): 850-859. doi:10.4161/rna.20378
95. Zhou L, Li K, Shi YL, et al. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. Pigment Cell Melanoma Res. 2012; 25(5): 602-611.
96. Qu L, Wei B Che HD, Zhou L, Mi QS, He CD. A novel mutation in exon 8 of C1 inhibitor gene (C1INH) abolishing the original stop codon leads to a dysfunctional protein in a large Chinese family with type I hereditary angioedema. Exp Dermatol. 2012; 21(10): 788-791.
97. Xu YP, Qi RQ, Chen WB, et al. Aging affects epidermal Langerhans cell development and function and alters their miRNA gene expression profile. Aging. 2012; 4(11): 742-754.
98. Mi QS, Xu YP, He W, Qi RQ, Zheng D, Zhou L. Deletion of microRNA miR-223 increases skin Langerhans cell cross-presentation. Int J Biochem Cell Biol. 2013; 45(2): 395-400. doi:10.1016/j.biocel.2012.11.004
99. Shi YL, Weiland M Li J, et al. MicroRNA expression profiling identifies potential serum biomarkers for non-segmental vitiligo. Pigment Cell Melanoma Res. 2013; 26(3): 418-421. doi:10.1111/pcmr.12086.
100. Chen WB, Gao L, Weiland M, Liu M, Zhou L, Mi QS. Loss of miRNAS in bone marrow prevents from STZ-mediated autoimmune diabetes but deletion of miR-155 does not. Cell cycle. 2013; 12(7): 1151-1152.
101. Meng DM, Wang L, Xu JR, Yan SL, Zhou L, Mi QS. Fabp4-Cre-mediated deletion of the miRNA-processing enzyme Dicer causes mouse embryonic lethality. Acta Diabetol. 2013; 50(5): 823-824. doi:10.1007/s00592-011-0335-4.
102. Wei QQ, Mi QS, Dong Z. The regulation and function of microRNAs in kidney diseases. IUBMB Life. 2013; 65(7): 602-614. doi:10.1002/iub.1174
103. Mi QS and Kenny JJ. Types of Tolerance Seen in Autoreactive Phosphocholine Specific B cells are Dependent on the Idiotype of the Receptors Expressed. Cell Mol Immuno. 2013; 10(4): 311-316. doi:10.1038/cmi.2013.17
104. Shi YL, Li K, Homozovi I, et al. Elevated circulating soluble interleukin-2 receptor in patients with non-segmental vitiligo in North American. J Dermatol Sci. 2013; 71(3): 212-214. doi:10.1016/j.jdermsci.2013.04.032
105. Chan DV, Gibson HM, Aufiero BM, et al. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 2014; 15(1): 25-32. doi:10.1038/gene.2013.57
106. Zhou L, Qi RQ, Liu M, et al. microRNA miR-17-92 cluster is highly expressed in epidermal Langerhans cells but not required for its development. Gene and Immunity. 2014; 15(1): 57-61.
107. Shi YL, Weiland M, Lim HW, Mi QS, Zhou L. Serum miRNA expression profiles change in autoimmune vitiligo in mice. Exp Dermatol. 2014; 23(2): 140-142. doi:10.1111/exd.12319
108. Liu X, Gao N, Dong C, et al. Flagellin-induced expression of CXCL10 mediates direct fungal killing and recruitment of NK cells to the cornea in response to Candida albicans infection. Eur J Immunol. 2014; 44(9): 2667-2679. doi:10.1002/eji.201444490.
109. Cui LL, Li J, Ren W, et al. Establishment of an animal model and drug intervention for hyperuricemic nephropathy. Gout and Hyperuricemia. 2014; 1(2): 73-81.
110. Dzinic SH, Chen K, Thakur A, et al. Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget. 2014. doi:10.18632/oncotarget.2615
111. Bhatt K, Wei Q, Pabla N, et al. MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury. J Am Soc Nephrol. 2015; 26(7): 1588-1596. doi:10.1681/ASN.2014050463
112. Zhou L, Shi YL, Li K, et al. Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res. 2015. doi:10.1111/pcmr.12355.
113. Barrie ES, Lodder M, Weinreb PH, et al. Role of ITGAE in the development of autoimmune diabetes in non-obese diabetic mice. J Endocrinol. 2015; 224(3): 235-243. doi:10.1530/JOE-14-0396
114. Li C, Li Z, Liu S, et al. Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese. Nat Commun. 2015; 6: 7041.

BOOK CHAPTERS

1. M. Chen, Q-S Mi. Melanocyte Tumor, bacterial and chlamydial diseases. In: Practical histopathology of skin. In: Chen M, et al, eds. Chapt 7, P; Chapt. 3. Guangdong Scientific and technological Press, 1994: 63-89.
2. Meagher C, Mi QS, Wagner M, Hussain S, Ly D, Delovitch TL. Studies on iNKT Cell Differentiation and Activation Reveal Potential Novel Therapies for Protection against Type 1 Diabetes. In: Yamamura T, Croxford L, eds. NKT Cells. 2006.
3. Zhou L, Zhong X, Mi QS, She JX. In Vitro Expanded CD8+ NKT-like Cells Possess Potent Cytotoxic and Immunosuppressive Activities. Advances in Medicine and Biology. 2011: 14.